We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vaxart Inc | NASDAQ:VXRT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0216 | 2.93% | 0.76 | 0.76 | 0.77 | 100 | 12:00:00 |
Presentation Information:
Title: Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in HumansSpeaker: Dr. Sean TuckerDate: Monday, July 18, 2022Time: 11:00 a.m. PT / 2:00 p.m. ET
Title: Mucosal rAd5 Immunization against SARS-CoV-2 Spike Elicits Cross-Reactive Nasal and Serum Neutralizing Antibodies and Protects Against Beta Variant Challenge in Non-Human Primates Speaker: Dr. Rebecca FlitterDate: Monday, July 18, 2022 Time: 11:00 a.m. PT / 2:00 p.m. ET
About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contacts
Vaxart Media Relations: | Investor Relations: |
Mark Herr | Andrew Blazier |
Vaxart, Inc. | FINN Partners |
mherr@vaxart.com | IR@Vaxart.com |
(203) 517-8957 | (646) 871-8486 |
1 Year Vaxart Chart |
1 Month Vaxart Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions